| Y-mAbs Therapeutics Inc. |
73042020101 |
Danyelza Injection, 40mg/10mg, single use vial |
2021-02-01 |
20368.0000 |
Y-mAbs' pricing decisions regarding the introductory WAC was determined after very thoughtful and careful consideration of a number of interdependent factors.
These factors include but are not limited to the following:
1. The clinical and economic value of the drug;
2. Market dynamics and competitive pricing and total cost of care within the drug's therapeutic category;
3. Discounts provided to customers for commercial and government channels;
4. Cost of comprehensive patient support programs to ensure patient access; and
5. Overall research and development costs & reinvestment into future R&D
Y-mAbs will use (digital and print) promotion that focuses on raising awareness of Danyelza as well as the deployment of a national sales force. |
None |
700 |
1 |
1 |
None |
None |
None |
None |
Y-mAbs has left the fields regarding acquisition blank because Danyelza was not acquired, but was developed by Y-mAbs. |
None |